Immune Targeting Systems develops synthetic vaccines intended to protect against mutating viruses, with a lead candidate FP-01 targeting influenza. The company says FP-01 aims to target all potential seasonal and pandemic influenza strains and protect people from severe influenza disease. The recent financing will progress FP-01 through to the completion of phase-II proof-of-concept efficacy studies. ITS will use the funds to evaluate its flu vaccine product candidate in phase I and phase II clinical trials and to assess safety and preliminary efficacy against multiple influenza virus strains. The company secured additional Series A equity funding to support these clinical development plans. ITS is based in London, UK.

Total raised

$14M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2010